The activation of FGF2-FGFR-driven signaling pathways by acquired resistance to EGFR-TKIs such as gefitinib and afatinib has been reported, primarily in NSCLC cells harboring EGFR mutation [14, 16]. This evidence concerns the gene FGF2 and non-small cell lung carcinoma.